<SEC-DOCUMENT>0001193125-23-306032.txt : 20231229
<SEC-HEADER>0001193125-23-306032.hdr.sgml : 20231229
<ACCEPTANCE-DATETIME>20231229172900
ACCESSION NUMBER:		0001193125-23-306032
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20231229
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231229
DATE AS OF CHANGE:		20231229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		231528715

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d673597d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20231229" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-12-29_to_2023-12-29">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-12-29_to_2023-12-29">0001062822</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="lxrx-20231229.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-12-29_to_2023-12-29"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-29</xbrli:startDate> <xbrli:endDate>2023-12-29</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-12-29_to_2023-12-29">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt:datemonthdayyearen">December&#160;29, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-12-29_to_2023-12-29">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-12-29_to_2023-12-29">000-30111</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-12-29_to_2023-12-29">76-0474169</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction of<br />incorporation or organization)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification Number)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-12-29_to_2023-12-29">2445 Technology Forest Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-12-29_to_2023-12-29">11th Floor</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-12-29_to_2023-12-29">The Woodlands</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-12-29_to_2023-12-29">77381</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices and Zip Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-12-29_to_2023-12-29">(281)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-12-29_to_2023-12-29">863-3000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-12-29_to_2023-12-29">Common stock, par value $0.001</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-12-29_to_2023-12-29">LXRX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2).</span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-12-29_to_2023-12-29" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On December 29, 2023, Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) entered into an Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup>&#160;(the &#8220;<span style="text-decoration:underline">Agreement</span>&#8221;) with Jefferies LLC, as sales agent (&#8220;<span style="text-decoration:underline">Jefferies</span>&#8221;), pursuant to which the Company may offer and sell, from time to time, through Jefferies (the &#8220;public offerings&#8221;), shares of its common stock, par value $0.001, having an aggregate sales price of up to $75,000,000 (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company is not obligated to sell any Shares under the Agreement. Subject to the terms and conditions of the Agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations to sell Shares from time to time based upon the Company&#8217;s instructions, including any price, time or size limits specified by the Company, subject to certain limitations. Under the Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration:underline">Securities Act</span>&#8221;), including block transactions, sales made directly on the Nasdaq Global Select Market or sales made into any other existing trading market of the Company&#8217;s common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (Registration <span style="white-space:nowrap">No.&#160;333-258564),</span> filed August&#160;6, 2021 and effective as of September&#160;14, 2021. The Company filed a prospectus supplement with the U.S. Securities and Exchange Commission on December&#160;29, 2023 in connection with the offer and sale of the Shares pursuant to the Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of Shares, reimburse legal fees and disbursements and provide Jefferies with customary indemnification and contribution rights. The Agreement will terminate as set forth in the Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">An affiliate (the &#8220;<span style="text-decoration:underline">Covered Stockholder</span>&#8221;) of Invus, L.P., the Company&#8217;s largest stockholder, has the right, pursuant to the Company&#8217;s Fifth Amended and Restated Certificate of Incorporation, in connection with any sales made pursuant to the Agreement to concurrently purchase a number of shares of the Company&#8217;s common stock sufficient to maintain its proportionate ownership interest in the Company after giving effect to such sales; provided, however, that in any given year, the Covered Stockholder may not exercise such right unless and until the Company has otherwise issued, in the aggregate, common stock pursuant to sales under the Agreement in an amount greater than two percent of the Company&#8217;s issued and outstanding common stock measured as of December&#160;31 of the preceding year. Should the Covered Stockholder choose to exercise such right, the Company expects that any shares sold to the Covered Stockholder pursuant thereto would occur in a concurrent private placement exempt from the registration requirements of the Securities Act, at the same price as the price to the public for the corresponding sales made under the Agreement (a &#8220;<span style="text-decoration:underline">concurrent private placement</span>&#8221; and, together with the public offerings, an &#8220;<span style="text-decoration:underline">offering</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from any offerings, if any, (i)&#160;to fund the commercial launch of INPEFA<sup style="font-size:75%; vertical-align:top">&#174;</sup> (sotagliflozin), (ii) to fund the continued research and development of its drug candidates and (iii)&#160;for working capital and other general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Agreement in this Current Report on Form <span style="white-space:nowrap">8-K</span> does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 1.1 hereto and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Vinson&#160;&amp; Elkins L.L.P., counsel to the Company, has issued a legal opinion relating to the validity of the Shares being offered pursuant to the Agreement. A copy of such legal opinion, including the consent included therein, is filed as Exhibit 5.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> shall not constitute an offer to sell or the solicitation of an offer to buy any Shares under the Agreement nor shall there be any sale of such Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#160;&#160;&#160;&#160;Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:91%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d673597dex11.htm">Open Market Sale Agreement<sup style="font-size:75%; vertical-align:top">SM</sup>, by and between Jefferies LLC and the Company, dated December&#160;29, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d673597dex51.htm">Opinion of Vinson&#160;&amp; Elkins L.L.P. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d673597dex51.htm">Consent of Vinson&#160;&amp; Elkins L.L.P. (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"><span style="white-space:nowrap">EX-104</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signatures </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Lexicon Pharmaceuticals, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: December&#160;29, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian T. Crum</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Brian T. Crum</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Senior Vice President and General Counsel</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d673597dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPEN MARKET SALE AGREEMENT<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">December&nbsp;29, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals,
Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the &#147;<B>Agent</B>&#148;),
shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<B>Common Shares</B>&#148;), having an aggregate offering price of up to $75,000,000 on the terms set forth in this agreement (this &#147;<B>Agreement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. DEFINITIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Certain Definitions</U>. For purposes of this Agreement, capitalized terms used herein and not otherwise defined shall have the
following respective meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Affiliate</B>&#148; of a Person means another Person that directly or indirectly, through one or
more intermediaries, controls, is controlled by, or is under common control with, such first- mentioned Person. The term &#147;control&#148; (including the terms &#147;controlling,&#148; &#147;controlled by&#148; and &#147;under common control
with&#148;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agency Period</B>&#148; means the period commencing on the date of this Agreement and expiring on the earliest to occur of
(x)&nbsp;the date on which the Agent shall have placed the Maximum Program Amount pursuant to this Agreement and (y)&nbsp;the date this Agreement is terminated pursuant to <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Floor Price</B>&#148; means the minimum price set by the Company in the Issuance Notice below which the Agent shall
not sell Shares during the applicable period set forth in the Issuance Notice, which may be adjusted by the Company at any time during the period set forth in the Issuance Notice by delivering written notice of such change to the Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Amount</B>&#148; means the aggregate Sales Price of the Shares to be sold by the Agent pursuant to any Issuance Notice. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><SUP STYLE="font-size:75%; vertical-align:top">SM</SUP>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>&#147;Open Market Sale Agreement&#148; is a service mark of Jefferies LLC<B> </B></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Notice</B>&#148; means a written notice delivered to the Agent by the
Company in accordance with this Agreement substantially in the form attached hereto as Exhibit A that is executed by its Chief Executive Officer, President or Chief Financial Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Notice Date</B>&#148; means any Trading Day during the Agency Period that an Issuance Notice is delivered pursuant to
<U>Section</U><U></U><U>&nbsp;3(b)(i)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Issuance Price</B>&#148; means the Sales Price less the Selling Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Maximum Program Amount</B>&#148; means, at any given point in time, Common Shares with an aggregate Sales Price of the lesser of
(a)&nbsp;the number or dollar amount of Common Shares registered under the effective Registration Statement (defined below) pursuant to which the offering is being made, (b)&nbsp;the number of authorized but unissued Common Shares (less Common
Shares issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#146;s authorized capital stock), (c) the number or dollar amount of Common Shares permitted to be sold under
Form <FONT STYLE="white-space:nowrap">S-3</FONT> (including General Instruction I.B.6 thereof, if applicable), or (d)&nbsp;the number or dollar amount of Common Shares for which the Company has filed a Prospectus (defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person</B>&#148; means an individual or a corporation, partnership, limited liability company, trust, incorporated or unincorporated
association, joint venture, joint stock company, governmental authority or other entity of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Principal Market</B>&#148;
means The Nasdaq Global Select Market or such other national securities exchange on which the Common Shares, including any Shares, are then listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sales Price</B>&#148; means the actual sale execution price of each Share placed by the Agent pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Selling Commission</B>&#148; means three percent (3.0%) of the gross proceeds of Shares sold pursuant to this Agreement, or as
otherwise agreed between the Company and the Agent with respect to any Shares sold pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Settlement
Date</B>&#148; means the second business day (or such other time as then specified for standard settlement cycles pursuant to applicable Commission rules) following each Trading Day during the period set forth in the Issuance Notice on which Shares
are sold pursuant to this Agreement, when the Company shall deliver to the Agent the amount of Shares sold on such Trading Day and the Agent shall deliver to the Company the Issuance Price received on such sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shares</B>&#148; shall mean the Company&#146;s Common Shares issued or issuable pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Trading Day</B>&#148; means any day on which the Principal Market is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to, and agrees with, the Agent that as of (1)&nbsp;the date of this Agreement, (2)&nbsp;each Issuance
Notice Date, (3)&nbsp;each Settlement Date, (4)&nbsp;each Triggering Event Date and (5)&nbsp;as of each Time of Sale (each of the times referenced above is referred to herein as a &#147;<B>Representation Date</B>&#148;), except as may be disclosed
in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before a Representation Date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement</U>. The Company has prepared and filed with the Commission a shelf registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> 258564) that contains a base prospectus (the &#147;<B>Base Prospectus</B>&#148;). Such registration statement registers the issuance and sale by the
Company of the Shares under the Securities Act. The Company may file one or more additional registration statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to
the Shares. Except where the context otherwise requires, such registration statement(s), including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, including all financial statements, exhibits and schedules
thereto and all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act as from time to time amended or supplemented, is herein
referred to as the &#147;<B>Registration Statement,</B>&#148; and the prospectus constituting a part of such registration statement(s), together with any prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Securities
Act relating to a particular issuance of the Shares, including all documents incorporated or deemed to be incorporated therein by reference pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, in each
case, as from time to time amended or supplemented, is referred to herein as the &#147;<B>Prospectus,</B>&#148; except that if any revised prospectus is provided to the Agent by the Company for use in connection with the offering of the Shares that
is not required to be filed by the Company pursuant to Rule 424(b) under the Securities Act, the term &#147;<B>Prospectus</B>&#148; shall refer to such revised prospectus from and after the time it is first provided to the Agent for such use. The
Registration Statement at the time it originally became effective is herein called the &#147;<B>Original Registration Statement.</B>&#148; As used in this Agreement, the terms &#147;amendment&#148; or &#147;supplement&#148; when applied to the
Registration Statement or the Prospectus shall be deemed to include the filing by the Company with the Commission of any document under the Exchange Act after the date hereof that is or is deemed to be incorporated therein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to financial statements and schedules and other information which is &#147;contained,&#148;
&#147;included&#148; or &#147;stated&#148; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is or is
deemed to be incorporated by reference in or otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date; and all references in this Agreement to
amendments or supplements to the Registration Statement or the Prospectus shall be deemed to mean and include, without limitation, the filing of any document under the Exchange Act which is or is deemed to be incorporated by reference in or
otherwise deemed under the Securities Act to be a part of or included in the Registration Statement or the Prospectus, as the case may be, as of any specified date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time the Original Registration Statement was declared effective and, if later, at the
time the Company&#146;s most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> was filed with the Commission, the Company met the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under
the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Compliance with Registration Requirements</U>. The Original Registration Statement and any Rule 462(b)
Registration Statement have been declared effective by the Commission under the Securities Act. The Company has complied to the Commission&#146;s satisfaction with all requests of the Commission for additional or supplemental information. No stop
order suspending the effectiveness of the Registration Statement or any Rule 462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, are
contemplated or threatened by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus when filed complied or will comply in all material respects with the
Securities Act and, if filed with the Commission through its Electronic Data Gathering, Analysis and Retrieval system (&#147;<B>EDGAR</B>&#148;) (except as may be permitted by Regulation S T under the Securities Act), was identical to the copy
thereof delivered to the Agent for use in connection with the issuance and sale of the Shares. Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto, at the time it became or becomes
effective and at each Representation Date, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. As of the date of this Agreement, the Prospectus and any Free Writing Prospectus (as defined below) considered together (collectively, the &#147;<B>Time of Sale
Information</B>&#148;) did not include any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus,
as amended or supplemented, as of its date and at each Representation Date, did not and will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule 462(b)
Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the
Agent expressly for use therein, it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in <U>Section</U><U></U><U>&nbsp;6</U> below. There are no contracts or other
documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. The Registration Statement and the offer and sale of the Shares as contemplated hereby
meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Ineligible Issuer
Status</U>. The Company is not an &#147;ineligible issuer&#148; in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Any Free Writing Prospectus that the Company is required to file pursuant to
Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act. Each Free Writing Prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d)
under the Securities Act or that was prepared by or on behalf of or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act including timely filing with the Commission or
retention where required and legending, and each such Free Writing Prospectus, as of its issue date and at all subsequent times through the completion of the issuance and sale of the Shares did not, does not and will not include any information that
conflicted, conflicts with or will conflict with the information contained in the Registration Statement or the Prospectus, including any document incorporated by reference therein. Except for the Free Writing Prospectuses, if any, and electronic
road shows, if any, furnished to the Agent before first use, the Company has not prepared, used or referred to, and will not, without the Agent&#146;s prior consent, prepare, use or refer to, any Free Writing Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Incorporated Documents</U>. The documents incorporated or deemed to be incorporated by reference in the Registration Statement and the
Prospectus, at the time they were filed with the Commission, complied in all material respects with the requirements of the Exchange Act, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exchange Act Compliance</U>. The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they
were or hereafter are filed with the Commission, and any Free Writing Prospectus or amendment or supplement thereto complied and will comply in all material respects with the requirements of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Statistical and Market-Related Data</U>. All statistical, demographic and market-related data included in the Registration Statement or
the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects or represent the Company&#146;s good faith estimates that are made on the basis thereof. To
the extent required, the Company has obtained the written consent for the use of such data from such sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Disclosure Controls
and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</U>. Except as otherwise disclosed in the Prospectus, the Company has established and maintains disclosure controls and procedures (as defined in Rules <FONT
STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act), which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is
made known to the Company&#146;s principal executive officer and its principal financial or accounting officer by others within those entities, within the time periods specified in the Commission&#146;s rules and forms; (ii)&nbsp;have been evaluated
by management of the Company for effectiveness as of the end of the Company&#146;s most recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established. Since the end of the
Company&#146;s most recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over
financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>This Agreement</U>. This Agreement has been duly authorized, executed and delivered
by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Authorization of the Shares</U>. The Shares have been or will be duly authorized for issuance and sale pursuant to
this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and, except as described in the Registration Statement and the Prospectus, the
issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>No Applicable Registration or Other Similar Rights</U>. Except otherwise disclosed in the Prospectus, there are no persons with
registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived or satisfied.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>No Material Adverse Change</U>. Except as otherwise disclosed in the Registration Statement and the Prospectus, subsequent to the
respective dates as of which information is given in the Registration Statement and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development that could be reasonably expected to result in a material adverse change, in
(A)&nbsp;the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company
and its subsidiaries, considered as one entity or (B)&nbsp;the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a &#147;<B>Material
Adverse Change</B>&#148;); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their
business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the
aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the capital stock or any material
increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other
subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Independent Accountants</U>. Ernst&nbsp;&amp; Young LLP, which has expressed its opinion with respect to the financial statements
(which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement and the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the
Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (&#147;<B>PCAOB</B>&#148;), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule <FONT
STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked
and who has not requested such registration to be withdrawn. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Financial Statements</U>. The financial statements filed with the Commission as a
part of the Registration Statement and the Prospectus comply as to form in all material respects with the requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Securities Act and present fairly in all material respects the
consolidated financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#146; equity and cash flows for the periods specified. Such financial statements
have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable
thereto in all material respects. No other financial statements or supporting schedules are required to be included in the Registration Statement or the Prospectus. The financial data set forth in each of the Registration Statement and the
Prospectus fairly present in all material respects the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Company&#146;s Accounting System</U>. Except as otherwise disclosed in the Prospectus, the Company and each of its subsidiaries make
and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles as applied in the United States and to maintain accountability for assets; (iii)&nbsp;access
to assets is permitted only in accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with
respect to any differences; and (v)&nbsp;the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the Prospectus fairly presents the information called for in all material
respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Incorporation and Good
Standing of the Company</U>. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate
its properties and to conduct its business as described in the Registration Statement and the Prospectus and to enter into and perform its obligations under this Agreement except to the extent that the failure to be in good standing or have such
power or authority would not result in a Material Adverse Change. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Texas and each other jurisdiction in which the conduct of its
business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not result in a Material Adverse Change. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Subsidiaries</U>. Each of the Company&#146;s &#147;subsidiaries&#148; (for purposes
of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing
under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement and the
Prospectus except to the extent that the failure to be in good standing or have such power or authority would not result in a Material Adverse Change. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or
limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the
failure to be so qualified or be in good standing would not result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company&#146;s subsidiaries have been duly
authorized and validly issued, are fully paid and nonassessable and, except as otherwise disclosed in the Prospectus, are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien,
encumbrance or adverse claim (except for such liens granted under that certain loan and security agreement, dated as of March&nbsp;17, 2022 (as amended and modified to the date hereof), among the Company, Lexicon Pharmaceuticals (New Jersey), Inc.,
Oxford Finance LLC, the lenders listed on Schedule 1.1 thereto and Oxford Finance Credit Fund III, LP. The Company does not own or control, directly or indirectly, any corporation, association or other entity that would constitute a significant
subsidiary as defined under Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> other than the subsidiaries listed in Exhibit 21 to the Company&#146;s most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Capitalization and Other Capital Stock Matters</U>. The authorized, issued and outstanding
capital stock of the Company is as set forth in the Registration Statement and the Prospectus, as of the date of such filing or the date of filing of any incorporated document with such information, under the caption &#147;Capitalization&#148;
(other than for subsequent issuances, if any, pursuant to employee benefit plans or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement and the Prospectus). The Common Shares (including the
Shares) conform in all material respects to the description thereof contained in the Prospectus. All of the issued and outstanding Common Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in
compliance with all federal and state securities laws. None of the outstanding Common Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company.
There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or
any of its subsidiaries other than those described in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Stock Exchange Listing</U>.
The Common Shares are registered pursuant to Section&nbsp;12(b) or 12(g) of the Exchange Act and are listed on the Principal Market, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the
registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Principal Market, nor has the Company received any notification that the Commission or the Principal Market is contemplating terminating such
registration or listing. To the Company&#146;s knowledge, it is in compliance in all material respects with all applicable listing requirements of the Principal Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U><FONT STYLE="white-space:nowrap">Non-Contravention</FONT> of Existing Instruments; No
Further Authorizations or Approvals Required</U>. Neither the Company nor any of its subsidiaries is in violation of its charter or by laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in
default (or, with the giving of notice or lapse of time, would be in default) (&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without
limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them
may be bound, or to which any of their respective properties or assets are subject, except for such Defaults as could not be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company&#146;s execution, delivery
and performance of this Agreement, consummation of the transactions contemplated hereby and the issuance and sale of the Shares will not contravene (i)&nbsp;the provisions of the charter or by laws, partnership agreement or operating agreement or
similar organizational documents, as applicable, of the Company or any subsidiary, (ii)&nbsp;any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a
whole, and (iii)&nbsp;any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries; except, in the case of clauses (ii)&nbsp;and (iii), as would not reasonably be expected to result in a
Material Adverse Change. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution, delivery and performance
of this Agreement and consummation of the transactions contemplated hereby, except such as (i)&nbsp;have been obtained or made by the Company and are in full force and effect under the Securities Act, (ii)&nbsp;as may be required under applicable
state securities or blue sky laws or FINRA (as defined below) and (iii)&nbsp;if not obtained, have not or would not reasonably be expected to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>No Material Actions or Proceedings</U>. Except as otherwise disclosed in the Prospectus, there is no action, suit, proceeding, inquiry
or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the
aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company exists, except as described in the Prospectus, or, to the knowledge of the Company, is imminent; and the Company is not aware of any
existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers or contractors that could result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Intellectual Property Rights</U>. Except as otherwise disclosed in the Registration Statement or the Prospectus, the Company and its
subsidiaries own, or have rights to use the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement and the Prospectus as
being owned or licensed by them and which are used in and necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, &#147;<B>Intellectual Property</B>&#148;) and, to the
Company&#146;s knowledge, the conduct of their respective businesses does not and will not infringe or misappropriate in any material respect any such rights of others. The Intellectual Property owned by the Company has not been adjudged by a court
of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Company&#146;s knowledge: (i)&nbsp;except as otherwise
disclosed in the Prospectus and with respect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to LX9211 (to which the Company has acquired an exclusive license), there are no third parties who have ownership, royalty, or exclusive license rights to any Intellectual Property owned by the
Company, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement and the Prospectus as licensed to the Company or one or more of its subsidiaries; and
(ii)&nbsp;there is no material infringement by third parties of any Intellectual Property owned by the Company. There is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the
Company&#146;s rights in or to any Intellectual Property licensed to the Company; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property owned by the Company; or (C)&nbsp;asserting that the Company or any of its
subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement or the Prospectus as under development, infringe or violate, any patent, trademark, trade name,
service name, copyright, trade secret or other intellectual rights of others. The Company and its subsidiaries have materially complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any
subsidiary, and all such agreements are, to the Company&#146;s knowledge, in full force and effect. To the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property.
The Company and its subsidiaries have taken reasonable steps to protect, maintain and safeguard Intellectual Property owned by the Company, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment
agreements and invention assignments with their employees, and, to the Company&#146;s knowledge, no employee of the Company is in or has been in violation of any term of any such agreement. The duty of candor and good faith as required by the United
States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property owned by the Company have been materially complied with; and in all foreign offices having similar
requirements, all such requirements have been materially complied with. The product candidates described in the Registration Statement and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of
one or more patents or patent applications owned by, or exclusively licensed to, the Company or any subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>All Necessary
Permits, etc</U>. Except as otherwise disclosed in the Prospectus, the Company and each subsidiary possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct
their respective businesses as currently conducted and as described in the Registration Statement or the Prospectus (&#147;<B>Permits</B>&#148;), except as would not reasonably be expected to result in a Material Adverse Change, and the Company has
not received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a
Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Manufacturing and Operations</U>. To the Company&#146;s knowledge, the manufacturing facilities and
operations of its suppliers or its subsidiaries are operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the of the U.S. Food and Drug Administration (the &#147;<B>FDA</B>&#148;) and
comparable drug regulatory agencies outside of the United States to which it is subject (collectively, the &#147;<B>Regulatory Authorities</B>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Federal Reserve</U>. The application of the proceeds received by the Company from the
issuance, sale and delivery of the Shares as described in Prospectus will not violate Regulation T, U or X of the Board of Governors of the Federal Reserve system or any other regulation of such Board of Governors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Title to Properties</U>. Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries have good and marketable
title to all of the real and personal property and other assets owned by them which is material to the business of the Company, in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other
defects except as do not materially affect the value of such property and do not interfere in any material respect with the use made and currently proposed to be made of such property by the Company. Except as otherwise disclosed in the Prospectus,
the real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with
the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>Tax Law Compliance</U>. Except as would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse
Change, the Company and its subsidiaries (i)&nbsp;have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and (ii)&nbsp;have paid all taxes required to be paid by any of them
and, if due and payable, any related or similar assessment, fine or penalty levied against any of them, except as may be being contested in good faith and by appropriate proceedings and for which adequate reserves are maintained in accordance with
generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Company Not an &#147;Investment Company</U>.&#148; The Company is not, and will not be,
either after receipt of payment for the Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement or the Prospectus, required to register as an &#147;investment
company&#148; under the Investment Company Act of 1940, as amended (the &#147;<B>Investment Company Act</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)
<U>Insurance</U>. The Company and each of its subsidiaries is insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which it is engaged. The
Company and its subsidiaries are in compliance with the terms of such policies and instruments in all material respects; and there are no material claims by the Company or any of its subsidiaries under any such policy or instrument as to which any
insurance company is denying liability or defending under a reservation of rights clause; neither the Company nor any such subsidiary has been refused any insurance coverage sought or applied for; and neither the Company nor any such subsidiary has
any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not result
in a Material Adverse Change, except as described in the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Dividend Restrictions</U>. Except as disclosed in the Prospectus, no subsidiary of
the Company is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock, from repaying to the Company any loans or advances to such subsidiary
from the Company or from transferring any of such subsidiary&#146;s property or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>No Price Stabilization or Manipulation; Compliance with Regulation M</U>. Neither the Company nor any of its subsidiaries has taken,
directly or indirectly, any action designed to or that reasonably would be expected to cause or result in stabilization or manipulation of the price of the Common Shares or of any &#147;reference security&#148; (as defined in Rule 100 of Regulation
M under the Exchange Act (&#147;<B>Regulation M</B>&#148;)) with respect to the Common Shares, whether to facilitate the sale or resale of the Shares or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Related Party Transactions</U>. There are no business relationships or related-party transactions involving the Company or any of its
subsidiaries or any other person required to be described in the Registration Statement or the Prospectus which have not been described as required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>FINRA Matters</U>. All of the information provided to the Agent or to counsel for the Agent by the Company, its counsel, its officers
and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Shares is true, complete and correct. The Company has been subject to the reporting
requirements under Section&nbsp;12 of the Exchange Act for at least 36 calendar months, and either (x)&nbsp;the aggregate market value of the Company&#146;s voting stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is at least
$150&nbsp;million or (y)&nbsp;alternatively, the aggregate market value of the Company&#146;s voting stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is $100&nbsp;million or more and the Company has had an annual trading volume
of such stock of three million shares or more. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>No Unlawful Contributions or Other Payments</U>. Except as otherwise disclosed in
the Prospectus, neither the Company nor any of its subsidiaries nor, to the best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate
for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <U>Compliance with Environmental Laws</U>. Except as described in the Prospectus and except as could not be expected, individually or in
the aggregate, to result in a Material Adverse Change, (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any applicable federal, state, local or foreign statute, law (including fundamental principles of common law), rule,
regulation or ordinance, including any judicial or administrative interpretation thereof, relating to pollution or protection of human health (to the extent relating to exposure to Hazardous Materials, defined below), the environment (including,
without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release of pollutants, contaminants, or hazardous or toxic wastes or
substances that are subject to regulation by any governmental authority (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous
Materials (collectively, &#147;<B>Environmental Laws</B>&#148;), (ii) the Company and its subsidiaries have all permits, authorizations and approvals required of them under Environmental Laws for their operations as currently conducted and are each
in compliance with the terms and conditions of such permits, authorizations and approvals, and (iii)&nbsp;the Company and its subsidiaries have not received written notice of any pending or threatened liability under any Environmental Law and, to
the knowledge of the Company, there is no event or occurrence that would reasonably be expected to result in the receipt of any such notice. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>ERISA Compliance</U>. Except as would not, individually or in the aggregate, result
in a Material Adverse Change: (i)&nbsp;the Company and its subsidiaries and any &#147;employee benefit plan&#148; (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations
thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained by the Company, its subsidiaries or their &#147;ERISA Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA; &#147;<B>ERISA
Affiliate</B>&#148; means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and
published interpretations thereunder (the &#147;<B>Code</B>&#148;) of which the Company or such subsidiary is a member; (ii)&nbsp;no &#147;reportable event&#148; (as defined under ERISA), other than an event for which the <FONT
STYLE="white-space:nowrap">30-day</FONT> notice period is waived, has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA
Affiliates; (iii)&nbsp;no &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any &#147;amount of
unfunded benefit liabilities&#148; (as defined under ERISA); (iv) neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (a)&nbsp;Title IV of ERISA with respect to
termination of, or withdrawal from, any &#147;employee benefit plan&#148; or (b)&nbsp;Sections 412, 4971, 4975 or 4980B of the Code; and (v)&nbsp;each &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or
any of their ERISA Affiliates that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would reasonably be expected to cause the loss of such
qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>Brokers</U>. Except as otherwise disclosed in the Prospectus, there is no broker, finder or other party that is
entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Compliance with Laws</U>. Except as otherwise disclosed in the Prospectus, the Company and its subsidiaries are in compliance with all
applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <U>Anti-Corruption and Anti-Bribery Laws</U>. Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, any
director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or
on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made or taken any act in furtherance of an
offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any
political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;<B>FCPA</B>&#148;), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance
of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses
in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>Money Laundering Laws</U>. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and
any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>Clinical Data and Regulatory Compliance</U>. The preclinical tests and clinical trials, and other studies (collectively,
&#147;studies&#148;) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are, to the Company&#146;s knowledge, being conducted in all material respects in
accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company; the descriptions of
the results of such studies do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading, and the Company and its subsidiaries have no knowledge of any other studies the results
of which reasonably call into question the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food
and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board
(collectively, the &#147;<B>Regulatory Agencies</B>&#148;) except where failure to do so would not result in a Material Adverse Change; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any
Regulatory Agency requiring the termination, suspension or material modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <U>FDA Compliance</U>. The Company: (A)&nbsp;is in compliance with the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et
seq.) and the regulations promulgated thereunder (the &#147;<B>FDCA</B>&#148;) except where failure to be so in compliance would not result in a Material Adverse Change; (B)&nbsp;has not received any FDA Form 483, written notice of adverse finding,
warning letter, untitled letter or other correspondence or written notice from the FDA alleging or asserting material noncompliance with the FDCA or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and
supplements or amendments thereto required under the FDCA (&#147;<B>Authorizations</B>&#148;); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of
any term of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Authorizations except where failure to possess or be so in compliance with such Authorizations would not reasonably be expected to result in a Material Adverse Change; (D)&nbsp;has not
received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any governmental entity or third party alleging that any product operation or activity is in material
violation of the FDCA or the terms of any Authorization and has no knowledge that the FDA or any governmental entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, which if resolved
adversely to the Company, would reasonably be expected to have a Material Adverse Change; (E)&nbsp;has not received written notice that the FDA or any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or
revoke any material Authorizations and has no knowledge that the FDA or any governmental entity is considering such action; and (F)&nbsp;has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments as required under the FDCA or any Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially
complete and correct on the date filed (or were corrected or supplemented by a subsequent submission), except where instances of failure to file, obtain, maintain or submit required documentation would not reasonably be expected to result in a
Material Adverse Change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <U>Sanctions</U>. Neither the Company nor any of its subsidiaries, nor, to the knowledge of the Company,
directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;<B>OFAC</B>&#148;) or the U.S. Department of State, the United Nations Security Council, the European Union, His Majesty&#146;s Treasury of the United Kingdom, or other
relevant sanctions authority (collectively, &#147;<B>Sanctions</B>&#148;); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without
limitation, Cuba, Iran, North Korea, Syria, and the Crimea, <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, and <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic regions of Ukraine and
the <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of Zaporizhzhia and Kherson Regions (collectively, the &#147;<B>Sanctioned Countries</B>&#148;); and the Company will not directly or indirectly use the proceeds of this
offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or
territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor,
investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing
or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <U>Sarbanes-Oxley</U>. The Company
and the Company&#146;s directors or officers, in their capacities as such, are in compliance, in all material respects, with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <U>Duties, Transfer Taxes, Etc</U>. No stamp or other issuance or transfer taxes or
duties are payable by the Agent in the United States or any political subdivision or taxing authority thereof or therein in connection with the execution, delivery or performance of this Agreement by the Company or the sale and delivery by the
Company of the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <U>Cybersecurity</U>. The Company&#146;s and its subsidiaries&#146; information technology assets and
equipment, computers, <FONT STYLE="white-space:nowrap">on-premise</FONT> and remote systems, networks, hardware, and databases (collectively, &#147;<B>IT Systems</B>&#148;) are reasonably adequate for the operation of the business of the Company and
its subsidiaries as currently conducted. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their
material confidential information and the integrity, operation, redundancy and security of all IT Systems and data, including &#147;Personal Data,&#148; used in connection with their businesses. &#147;<B>Personal Data</B>&#148; means (i)&nbsp;a
natural person&#146;s name, street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number,
or bank account information; (ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data,&#148; &#147;personal information,&#148; or
similar term as defined by CCPA (as defined below), CPRA (as defined below), GDPR (as defined below) or any other applicable Privacy Laws; (iv)&nbsp;any information which would qualify as &#147;protected health information&#148; under the Health
Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, &#147;<B>HIPAA</B>&#148;); and (v)&nbsp;any other piece of information that, either alone or in
combination with another piece of information, allows for the identification of such natural person, his or her family or household, or a device, or permits the collection or analysis of any data related to an identified person&#146;s health or
sexual orientation, and together with all proprietary or confidential information of the Company, &#147;Sensitive Data.&#148; In the past three years, there have been no breaches, violations, outages or unauthorized uses of or accesses to such
Sensitive Data or IT Systems, except for those that have been remedied without material cost or liability or the duty to notify any other person or governmental authority under Privacy Laws (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <U>Compliance with Data Privacy Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with
all applicable foreign, state and federal data privacy and security laws and regulations, including without limitation HIPAA, the European Union General Data Protection Regulation (&#147;<B>EU GDPR</B>&#148;) (EU 2016/679) and the United Kingdom
General Data Protection Regulation (&#147;<B>UK GDPR</B>&#148;), and all state privacy laws (including the California Consumer Privacy Act (&#147;<B>CCPA</B>&#148;), California Privacy Rights Act (&#147;<B>CPRA</B>&#148;) and similar laws in any
other states) (collectively, the &#147;<B>Privacy Laws</B>&#148;). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps to ensure compliance in all material respects with
the Company&#146;s internal and external policies and procedures relating to data privacy and security and the collection, processing, storage, use, disclosure, handling, transfer and analysis of Sensitive Data (the &#147;<B>Policies</B>&#148;). The
Company further certifies that neither it nor any subsidiary: (i)&nbsp;has received written notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws; (ii)&nbsp;is currently
conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action initiated by a governmental authority pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or settlement agreement
issued by a governmental authority that imposes any obligation or liability under any Privacy Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <U>Other Underwriting Agreements</U>. The Company is not a party to any agreement with
an agent or underwriter other than the Agent for any other &#147;at the market&#148; or continuous equity transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <U>Compliance
with Health Care Laws</U>. The Company and its subsidiaries are, and at all times have been, in compliance with all applicable Health Care Laws, except to the extent that any <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not,
individually or in the aggregate, reasonably be expected to result in a Material Adverse Change. For purposes of this Agreement, &#147;<B>Health Care Laws</B>&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301
et seq.), the Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the
Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the civil
monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusion law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and applicable laws governing government funded or sponsored healthcare programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42
U.S.C. Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable
federal, state, local or foreign laws or regulatory bodies; and (vi)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii)&nbsp;the directives and
regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit,
proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws
nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened, except in each case as would not, individually or in the aggregate, reasonably be
expected to result in a Material Adverse Change. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as
required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or
supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any
governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from
participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to
result in debarment, suspension, or exclusion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <U>Forward Looking Statements</U>. No forward-looking statement (within the meaning of
Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) contained in Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer or representative of the Company or any of its subsidiaries and delivered to the Agent or counsel for
the Agent in connection with an issuance of Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby on the date of such certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges that the Agent and, for purposes of the opinions to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U>
hereof, counsel to the Company and counsel to the Agent, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. ISSUANCE AND SALE OF COMMON SHARES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Sale of Securities</U>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company and the Agent agree that the Company may from time to time seek to sell Shares through the Agent, acting as sales agent, or directly to the Agent, acting as principal, as follows, with an aggregate Sales
Price of up to the Maximum Program Amount, based on and in accordance with Issuance Notices as the Company may deliver, during the Agency Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Mechanics of Issuances</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Issuance Notice</U>. Upon the terms and subject to the conditions set forth herein, on any Trading Day during the Agency Period on
which the conditions set forth in <U>Section</U><U></U><U>&nbsp;5(a)</U> and <U>Section</U><U></U><U>&nbsp;5(b)</U> shall have been satisfied, the Company may exercise its right to request an issuance of Shares by delivering to the Agent an Issuance
Notice; provided, however, that (A)&nbsp;in no event may the Company deliver an Issuance Notice to the extent that (I)&nbsp;the sum of (x)&nbsp;the aggregate Sales Price of the requested Issuance Amount, plus (y)&nbsp;the aggregate Sales Price of
all Shares issued under all previous Issuance Notices effected pursuant to this Agreement, would exceed the Maximum Program Amount; and (B)&nbsp;prior to delivery of any Issuance Notice, the period set forth for any previous Issuance Notice shall
have expired or been terminated. An Issuance Notice shall be considered delivered on the Trading Day that it is received by e mail to the persons set forth in Schedule A hereto and confirmed by the Company by telephone (including a voicemail message
to the persons so identified), with the understanding that, with adequate prior written notice, the Agent may modify the list of such persons from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Agent Efforts</U>. Upon the terms and subject to the conditions set forth in this Agreement, upon the receipt of an Issuance Notice,
the Agent will use its commercially reasonable efforts consistent with its normal sales and trading practices to place the Shares with respect to which the Agent has agreed to act as sales agent, subject to, and in accordance with the information
specified in, the Issuance Notice, unless the sale of the Shares described therein has been suspended, cancelled or otherwise terminated in accordance with the terms of this Agreement. For the avoidance of doubt, the parties to this Agreement may
modify an Issuance Notice at any time provided they both agree in writing to any such modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Method of Offer and Sale</U>. The Shares may be offered and sold (A)&nbsp;in
negotiated transactions with the consent of the Company or (B)&nbsp;by any other method permitted by law deemed to be an &#147;<B>at the market offering</B>&#148; as defined in Rule 415(a)(4) under the Securities Act, including block transactions,
sales made directly on the Principal Market or sales made into any other existing trading market of the Common Shares. Nothing in this Agreement shall be deemed to require either party to agree to the method of offer and sale specified in the
preceding sentence, and (except as specified in clause (A)&nbsp;above) the method of placement of any Shares by the Agent shall be at the Agent&#146;s discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>Confirmation to the Company</U>. If acting as sales agent hereunder, the Agent will provide written confirmation to the Company no
later than the opening of the Trading Day next following the Trading Day on which it has placed Shares hereunder setting forth the number of shares sold on such Trading Day, the corresponding Sales Price and the Issuance Price payable to the Company
in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Settlement</U>. Each issuance of Shares will be settled on the applicable Settlement Date for such issuance of
Shares and, subject to the provisions of <U>Section</U><U></U><U>&nbsp;5</U>, on or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Agent or its
designee&#146;s account at The Depository Trust Company through its Deposit/Withdrawal At Custodian (DWAC) System, or by such other means of delivery as may be mutually agreed upon by the parties hereto and, upon receipt of such Shares, which in all
cases shall be freely tradable, transferable, registered shares in good deliverable form, the Agent will deliver, by wire transfer of immediately available funds, the related Issuance Price in same day funds delivered to an account designated by the
Company prior to the Settlement Date. The Company may sell Shares to the Agent as principal at a price agreed upon at each relevant time Shares are sold pursuant to this Agreement (each, a &#147;<B>Time of Sale</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) <U>Suspension or Termination of Sales</U>. Consistent with standard market settlement practices, the Company or the Agent may, upon
notice to the other party hereto in writing or by telephone (confirmed immediately by verifiable <FONT STYLE="white-space:nowrap">e-mail),</FONT> suspend any sale of Shares, and the period set forth in an Issuance Notice shall immediately terminate;
provided, however, that (A)&nbsp;such suspension and termination shall not affect or impair either party&#146;s obligations with respect to any Shares placed or sold hereunder prior to the receipt of such notice; (B)&nbsp;if the Company suspends or
terminates any sale of Shares after the Agent confirms such sale to the Company, the Company shall still be obligated to comply with <U>Section</U><U></U><U>&nbsp;3(b)(v)</U> with respect to such Shares; and (C)&nbsp;if the Company defaults in its
obligation to deliver Shares on a Settlement Date, the Company agrees that it will hold the Agent harmless against any loss, claim, damage or expense (including, without limitation, penalties, interest and reasonable legal fees and expenses), as
incurred, arising out of or in connection with such default by the Company. The parties hereto acknowledge and agree that, in performing its obligations under this Agreement, the Agent may borrow Common Shares from stock lenders in the event that
the Company has not delivered Shares to settle sales as required by subsection (v)&nbsp;above, and may use the Shares to settle or close out such borrowings. The Company agrees that no such notice shall be effective against the Agent unless it is
made to the persons identified in writing by the Agent pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(</U><U>i</U><U>)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) <U>No Guarantee of Placement, Etc</U>. The Company acknowledges and agrees that
(A)&nbsp;there can be no assurance that the Agent will be successful in placing Shares; (B)&nbsp;the Agent will incur no liability or obligation to the Company or any other Person if it does not sell Shares; and (C)&nbsp;the Agent shall be under no
obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed by the Agent and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) <U>Material <FONT STYLE="white-space:nowrap">Non-Public</FONT> Information</U>. Notwithstanding any other provision of this Agreement,
the Company and the Agent agree that the Company shall not deliver any Issuance Notice to the Agent, and the Agent shall not be obligated to place any Shares, during any period in which the Company is in possession of material <FONT
STYLE="white-space:nowrap">non-public</FONT> information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Fees</U>. As compensation for services rendered, the Company shall pay
to the Agent, on the applicable Settlement Date, the Selling Commission for the applicable Issuance Amount (including with respect to any suspended or terminated sale pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(vi)</U>) by the Agent deducting the
Selling Commission from the applicable Issuance Amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses</U>. The Company agrees to pay all costs, fees and expenses
incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the issuance and delivery of the Shares (including
all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Shares; (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the Company&#146;s issuance and the Agent&#146;s sale
of the Shares; (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors; (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing,
shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Prospectus, any Free Writing Prospectus (as defined below) prepared by or on behalf of, used by,
or referred to by the Company, and all amendments and supplements thereto, and this Agreement; (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Agent in connection with qualifying or registering (or
obtaining exemptions from the qualification or registration of) all or any part of the Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by the Agent, preparing and
printing a &#147;<B>Blue Sky Survey</B>&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Agent of such qualifications, registrations, determinations and exemptions; (vii)&nbsp;the reasonable fees and
disbursements of the Agent&#146;s counsel, including the reasonable fees and expenses of counsel for the Agent in connection with, FINRA review, if any, and approval of the Agent&#146;s participation in the offering and distribution of the Shares;
(viii)&nbsp;the filing fees incident to FINRA review, if any; (ix)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in connection with the marketing of the offering of the Shares,
including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in
connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and of the Agent and any such consultants, and the cost of any aircraft
chartered in connection with the road show; and (x)&nbsp;the fees and expenses associated with listing the Shares on the Principal Market. The fees and disbursements of Agent&#146;s counsel pursuant to subsections (vi)&nbsp;and (vii) above shall not
exceed (A) $75,000 in connection with execution of this Agreement, (B) $25,000 in connection with each Triggering Event Date (as defined below) involving the filing of a Form <FONT STYLE="white-space:nowrap">10-K</FONT> on which the Company is
required to provide a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> and (C) $15,000 in connection with each other Triggering Event Date (as defined below) on which the Company is required to provide a certificate pursuant to
<U>Section</U><U></U><U>&nbsp;4(o)</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4. ADDITIONAL COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company covenants and agrees with the Agent as follows, in addition to any other covenants and agreements made elsewhere in this
Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Exchange Act Compliance</U>. During the Agency Period, the Company shall (i)&nbsp;use its reasonable best efforts to
file, on a timely basis, with the Commission all reports and documents required to be filed under Section&nbsp;13, 14 or 15 of the Exchange Act in the manner and within the time periods required by the Exchange Act; and (ii)&nbsp;either (A) include
in its quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and its annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> a summary detailing, for the relevant reporting period, (1)&nbsp;the number of Shares sold
through the Agent pursuant to this Agreement and (2)&nbsp;the net proceeds received by the Company from such sales or, (B)&nbsp;in the Company&#146;s sole discretion, prepare a prospectus supplement containing, or include in such other filing
permitted by the Securities Act or Exchange Act (each an &#147;<B>Interim Prospectus Supplement</B>&#148;), such summary information and, at least once a quarter and subject to this <U>Section</U><U></U><U>&nbsp;4</U>, file such Interim Prospectus
Supplement pursuant to Rule 424(b) under the Securities Act (and within the time periods required by Rule 424(b) and Rule 430B under the Securities Act)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Securities Act Compliance</U>. After the date of this Agreement, the Company shall promptly advise the Agent in writing (i)&nbsp;of the
receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;of the time and date of any filing of any post-effective amendment to the Registration Statement, any Rule 462(b) Registration
Statement or any amendment or supplement to the Prospectus, any Free Writing Prospectus; (iii)&nbsp;of the time and date that any post-effective amendment to the Registration Statement or any Rule 462(b) Registration Statement becomes effective; and
(iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto, any Rule 462(b) Registration Statement or any amendment or supplement to the Prospectus
or of any order preventing or suspending the use of any Free Writing Prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Common Shares from any securities exchange upon which they are
listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its commercially
reasonable efforts to obtain the lifting of such order as soon as practicable. Additionally, the Company agrees that it shall comply with the provisions of Rule 424(b) and Rule 433, as applicable, under the Securities Act and will use its reasonable
efforts to confirm that any filings made by the Company under such Rule 424(b) or Rule 433 were received in a timely manner by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Amendments and Supplements to the Prospectus and Other Securities Act Matters</U>. If any event shall occur or condition exist as a
result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances when the Prospectus is delivered to a purchaser, not misleading, or if in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opinion of the Agent or counsel for the Agent it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, including the Securities Act, the Company agrees
(subject to <U>Section</U><U></U><U>&nbsp;4(d)</U> and <U>Section</U><U></U><U>&nbsp;4(f)</U>) to promptly prepare, file with the Commission and furnish at its own expense to the Agent, amendments or supplements to the Prospectus so that the
statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the
Prospectus is delivered to a purchaser, be misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law including the Securities Act. Neither the Agent&#146;s consent to, or delivery of, any such amendment or
supplement shall constitute a waiver of any of the Company&#146;s obligations under <U>Section</U><U></U><U>&nbsp;4(d)</U> and <U>Section</U><U></U><U>&nbsp;4(f)</U>. Notwithstanding the foregoing, the Company shall not be required to file such
amendment or supplement if there is no pending Issuance Notice and the Company believes that it is in its best interest not to file such amendment or supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Agent</U><U>&#146;</U><U>s Review of Proposed Amendments and Supplements</U>. Prior to amending or supplementing the Registration
Statement (including any registration statement filed under Rule 462(b) under the Securities Act), insofar as such proposed amendment or supplement relates to the Shares, or the Prospectus (excluding any amendment or supplement through incorporation
of any report filed under the Exchange Act), the Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each such proposed amendment or supplement, and the Company
shall not file or use any such proposed amendment or supplement without the Agent&#146;s prior consent, and the Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus
required to be filed pursuant to such Rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Use of Free Writing Prospectus</U>. Neither the Company nor the Agent has prepared,
used, referred to or distributed, or will prepare, use, refer to or distribute, without the other party&#146;s prior written consent, any &#147;written communication&#148; that constitutes a &#147;free writing prospectus&#148; as such terms are
defined in Rule 405 under the Securities Act with respect to the offering contemplated by this Agreement (any such free writing prospectus being referred to herein as a &#147;<B>Free Writing Prospectus</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Free Writing Prospectuses</U>. The Company shall furnish to the Agent for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto to be prepared by or on behalf of, used by, or referred to by the Company insofar as such proposed amendment or supplement relates
to the Shares or the transactions contemplated hereby, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Agent&#146;s consent, which shall not be unreasonably
withheld, conditioned or delayed. The Company shall furnish to the Agent, without charge, as many copies of any free writing prospectus prepared by or on behalf of, or used by the Company insofar as such proposed amendment or supplement relates to
the Shares or the transactions contemplated hereby, as the Agent may reasonably request. If at any time when a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with
sales of the Shares (but in any event if at any time through and including the date of this Agreement) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or
referred to by the Company conflicted or would conflict </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict or so that
the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances prevailing at such subsequent time, not misleading, as the case may be; provided, however, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Agent for review, a reasonable amount
of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the
Agent&#146;s consent, which shall not be unreasonably withheld, conditioned or delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Filing of Agent Free Writing
Prospectuses</U>. The Company shall not take any action that would result in the Agent or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of
the Agent that the Agent otherwise would not have been required to file thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Copies of Registration Statement and
Prospectus</U>. After the date of this Agreement through the last time that a prospectus is required by the Securities Act (including, without limitation, pursuant to Rule 173(d)) to be delivered in connection with sales of the Shares, the Company
agrees to furnish the Agent with copies (which may be electronic copies) of the Registration Statement and each amendment thereto, and with copies (which may be electronic copies) of the Prospectus and each amendment or supplement thereto in the
form in which it is filed with the Commission pursuant to the Securities Act or Rule 424(b) under the Securities Act, both in such quantities as the Agent may reasonably request from time to time; and, if the delivery of a prospectus is required
under the Securities Act or under the blue sky or securities laws of any jurisdiction at any time on or prior to the applicable Settlement Date for any period set forth in an Issuance Notice in connection with the offering or sale of the Shares and
if at such time any event has occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made when such Prospectus is delivered, not misleading, or, if for any other reason it is necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act
any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, to notify the Agent and to request that the Agent suspend offers to sell Shares (and, if so notified, the Agent shall cease such
offers as soon as practicable); and if the Company decides to amend or supplement the Registration Statement or the Prospectus as then amended or supplemented, to advise the Agent promptly by telephone (with confirmation in writing) and to prepare
and cause to be filed promptly with the Commission an amendment or supplement to the Registration Statement or the Prospectus as then amended or supplemented that will correct such statement or omission or effect such compliance; provided, however,
that if during such same period the Agent is required to deliver a prospectus in respect of transactions in the Shares, the Company shall promptly prepare and file with the Commission such an amendment or supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Blue Sky Compliance</U>. The Company shall cooperate with the Agent and counsel for
the Agent to qualify or register the Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky laws or Canadian provincial securities laws of those jurisdictions designated by the Agent, shall comply with
such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would
subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Agent promptly of the suspension of the
qualification or registration of (or any such exemption relating to) the Shares for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order
suspending such qualification, registration or exemption, the Company shall use its commercially reasonable efforts to obtain the withdrawal thereof as soon as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <U>Earnings Statement</U>. As soon as practicable, the Company will make generally available to its security holders and to the Agent an
earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the date of this Agreement which shall satisfy the provisions of Section&nbsp;11(a) of
the Securities Act and Rule 158 under the Securities Act; provided that the Company will be deemed to have furnished such statement to its security holders and the Agent to the extent such statement is filed with the Commission on EDGAR or any
successor system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Listing; Reservation of Shares</U>. The Company will use commercially reasonable efforts to (a)&nbsp;maintain
the listing of the Shares on the Principal Market; and (b)&nbsp;reserve and keep available Shares for the purpose of enabling the Company to satisfy its obligations under this Agreement (subject to the Maximum Program Amount at any given point in
time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Transfer Agent</U>. The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Due Diligence</U>. During the term of this Agreement, the Company will reasonably cooperate with any reasonable due diligence
review conducted by the Agent in connection with the transactions contemplated hereby, including, without limitation, providing information and, upon reasonable notice, making available documents and senior corporate officers, during normal business
hours and at the Company&#146;s principal offices, as the Agent may reasonably request from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Representations and
Warranties</U>. The Company acknowledges that each delivery of an Issuance Notice and each delivery of Shares on a Settlement Date shall be deemed to be (i)&nbsp;an affirmation to the Agent that the representations and warranties of the Company
contained in or made pursuant to this Agreement are true and correct as of the date of such Issuance Notice or of such Settlement Date, as the case may be, as though made at and as of each such date, except as may be disclosed in the Prospectus
(including any documents incorporated by reference therein and any supplements thereto); and (ii)&nbsp;an undertaking that the Company will advise the Agent if any of such representations and warranties will not be true and correct as of the
Settlement Date for the Shares relating to such Issuance Notice, as though made at and as of each such date (except that such representations and warranties shall be deemed to relate to the Registration Statement and the Prospectus as amended and
supplemented relating to such Shares). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Deliverables at Triggering Event Dates; Certificates</U>. The Company agrees that on
or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) the filing of the Prospectus or the amendment or supplement of any Registration Statement or Prospectus (other than a prospectus supplement
relating solely to an offering of securities other than the Shares or a prospectus filed pursuant to <U>Section</U><U></U><U>&nbsp;4(a)(ii)(B)</U>), by means of a post-effective amendment, sticker or supplement, but not by means of incorporation of
documents by reference into the Registration Statement or Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) the filing with the Commission of an annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> or a quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> (including any Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> or Form <FONT STYLE="white-space:nowrap">10-Q/A</FONT> containing
amended financial information or a material amendment to the previously filed annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> or quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q),</FONT> in each case, of the Company;
or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) the filing with the Commission of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company containing
amended financial information (other than information &#147;furnished&#148; pursuant to Item 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or to provide disclosure pursuant to Item 8.01 of Form
<FONT STYLE="white-space:nowrap">8-K</FONT> relating to reclassification of certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No.&nbsp;144) that is material to the offering of securities of
the Company in the Agent&#146;s reasonable discretion; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(any such event, a &#147;<B>Triggering Event Date</B>&#148;), the Company shall furnish the Agent
(but in the case of clause (C)&nbsp;above only if the Agent reasonably determines that the information contained in such current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company is material to a holder of Common Shares and
informs the Company in writing of such determination) with a certificate as of the Triggering Event Date, in the form and substance satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its
counsel, modified, as necessary, to relate to the Registration Statement and the Prospectus as amended or supplemented, (A)&nbsp;confirming that the representations and warranties of the Company contained in this Agreement are true and correct,
(B)&nbsp;confirming that the Company has performed all of its obligations hereunder to be performed on or prior to the date of such certificate and as to the matters set forth in <U>Section</U><U></U><U>&nbsp;5(a)(iii)</U> hereof, and
(C)&nbsp;containing any other certification that the Agent shall reasonably request. The requirement to provide a certificate under this <U>Section</U><U></U><U>&nbsp;4(o)</U> shall be waived for any Triggering Event Date occurring at a time when no
Issuance Notice is pending or a suspension is in effect, which waiver shall continue until the earlier to occur of the date the Company delivers instructions for the sale of Shares hereunder (which for such calendar quarter shall be considered a
Triggering Event Date) and the next occurring Triggering Event Date. Notwithstanding the foregoing, if the Company subsequently decides to sell Shares following a Triggering Event Date when a suspension was in effect and did not provide the Agent
with a certificate under this <U>Section</U><U></U><U>&nbsp;4(o)</U>, then before the Company delivers the instructions for the sale of Shares or the Agent sells any Shares pursuant to such instructions, the Company shall provide the Agent with a
certificate in conformity with this <U>Section</U><U></U><U>&nbsp;4(o)</U> dated as of the date that the instructions for the sale of Shares are issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Legal Opinions</U>. On or prior to the date of the first Issuance Notice and on or
prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> for which no waiver is applicable and excluding the date of this Agreement, a negative
assurances letter and the written legal opinion of Vinson&nbsp;&amp; Elkins L.L.P., counsel to the Company, Brian T. Crum, Vice President and General Counsel of the Company and Max Bachrach, Ph.D., intellectual property counsel for the Company, each
dated the date of delivery, in form and substance reasonably satisfactory to Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel, modified, as necessary, to relate to the Registration Statement
and the Prospectus as then amended or supplemented. In lieu of such opinions for subsequent periodic filings, in the discretion of the Agent, the Company may furnish a reliance letter from such counsel to the Agent, permitting the Agent to rely on a
previously delivered opinion letter, modified as appropriate for any passage of time or Triggering Event Date (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or
supplemented as of such Triggering Event Date). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Comfort Letter</U>. On or prior to the date of the first Issuance Notice and on or
prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> for which no waiver is applicable and excluding the date of this Agreement, the Company
shall cause Ernst&nbsp;&amp; Young LLP, the independent registered public accounting firm who has audited the financial statements included or incorporated by reference in the Registration Statement, to furnish the Agent a comfort letter, dated the
date of delivery, in form and substance reasonably satisfactory to the Agent and its counsel, substantially similar to the form previously provided to the Agent and its counsel; provided, however, that any such comfort letter will only be required
on the Triggering Event Date specified to the extent that it contains financial statements filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Prospectus. If requested by the Agent, the
Company shall also cause a comfort letter to be furnished to the Agent on the date of occurrence of any material transaction or event requiring the filing of a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> containing material
amended financial information of the Company, including the restatement of the Company&#146;s financial statements. The Company shall be required to furnish no more than one comfort letter hereunder per each filing of an annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> or a quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)
<U>Secretary</U><U>&#146;</U><U>s Certificate</U>. On or prior to the date of the first Issuance Notice and on or prior to each Triggering Event Date with respect to which the Company is obligated to deliver a certificate pursuant to
Section&nbsp;4(o) for which no waiver is applicable and excluding the date of this Agreement, the Company shall furnish the Agent a certificate executed by the Secretary of the Company, signing in such capacity, dated the date of delivery
(i)&nbsp;certifying that attached thereto are true and complete copies of the resolutions duly adopted by the Board of Directors of the Company authorizing the execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby (including, without limitation, the issuance of the Shares pursuant to this Agreement), which authorization shall be in full force and effect on and as of the date of such certificate, (ii)&nbsp;certifying and attesting to the
office, incumbency, due authority and specimen signatures of each Person who executed this Agreement for or on behalf of the Company, and (iii)&nbsp;containing any other certification that the Agent shall reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Agent&#146;s Own Account; Clients&#146; Account</U>. The Company consents to the
Agent trading, in compliance with applicable law, in the Common Shares for the Agent&#146;s own account and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Investment Limitation</U>. The Company shall not invest, or otherwise use the proceeds received by the Company from its sale of the
Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Market Activities</U>. The Company will not take, directly or indirectly, any action designed to or that might be reasonably expected
to cause or result in stabilization or manipulation of the price of the Shares or any other reference security, whether to facilitate the sale or resale of the Shares or otherwise, and the Company will, and shall cause each of its affiliates to,
comply with all applicable provisions of Regulation M. If the limitations of Rule 102 of Regulation M (&#147;<B>Rule 102</B>&#148;) do not apply with respect to the Shares or any other reference security pursuant to any exception set forth in
Section (d)&nbsp;of Rule 102, then promptly upon notice from the Agent (or, if later, at the time stated in the notice), the Company will, and shall cause each of its affiliates to, comply with Rule 102 as though such exception were not available
but the other provisions of Rule 102 (as interpreted by the Commission) did apply. The Company shall promptly notify the Agent if it no longer meets the requirements set forth in Section (d)&nbsp;of Rule 102. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Notice of Other Sale</U>. Without the written consent of the Agent, the Company will not, directly or indirectly, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of any Common Shares or securities convertible into or exchangeable for Common Shares (other than Shares hereunder), warrants or any rights to purchase or acquire Common Shares, or
effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Common Shares, during the period beginning on the third Trading Day immediately prior to the date on which any
Issuance Notice is delivered to the Agent hereunder and ending on the third Trading Day immediately following the Settlement Date with respect to Shares sold pursuant to such Issuance Notice; and will not directly or indirectly enter into any other
&#147;at the market&#148; or continuous equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Shares (other than the Shares offered pursuant to this Agreement) or securities convertible
into or exchangeable for Common Shares, warrants or any rights to purchase or acquire, Common Shares prior to the termination of this Agreement; provided, however, that such restrictions will not be required in connection with the Company&#146;s
(i)&nbsp;issuance or sale of Common Shares, options to purchase Common Shares or Common Shares issuable upon the exercise of options or other equity awards pursuant to any employee or director share option, incentive or benefit plan, share purchase
or ownership plan, long-term incentive plan, dividend reinvestment plan, inducement award under Nasdaq rules or other compensation plan of the Company or its subsidiaries, as in effect on the date of this Agreement, (ii)&nbsp;issuance or sale of
Common Shares issuable upon exchange, conversion or redemption of securities or the exercise or vesting of warrants, options or other equity awards outstanding at the date of this Agreement, (iii)&nbsp;issuance or sale of Common Shares or securities
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible into or exchangeable for Common Shares as consideration for mergers, acquisitions, other business combinations, joint ventures or strategic alliances occurring after the date of this
Agreement which are not used for capital raising purposes; provided, that the aggregate number of Common Shares or securities convertible into or exchangeable for Common Shares issued in connection with all such acquisitions and other transactions
does not exceed 5% of the aggregate number of Common Shares outstanding immediately following the offering of Shares pursuant to this Agreement and (vi)&nbsp;modification of any outstanding options, warrants of any rights to purchase or acquire
Common Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5. CONDITIONS TO DELIVERY OF ISSUANCE NOTICES AND TO SETTLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Conditions Precedent to the Right of the Company to Deliver an Issuance Notice and the Obligation of the Agent to Sell Shares</U>. The
right of the Company to deliver an Issuance Notice hereunder is subject to the satisfaction, on the date of delivery of such Issuance Notice, and the obligation of the Agent to use its commercially reasonable efforts to place Shares during the
applicable period set forth in the Issuance Notice is subject to the satisfaction, on each Trading Day during the applicable period set forth in the Issuance Notice, of each of the following conditions: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Accuracy of the Company&#146;s Representations and Warranties; Performance by the Company</U>. The Company shall have delivered the
certificate required to be delivered pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U> on or before the date on which delivery of such certificate is required pursuant to <U>Section</U><U></U><U>&nbsp;4(o)</U>. The Company shall have performed,
satisfied and complied with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such date, including, but not limited to, the covenants contained in
<U>Section</U><U></U><U>&nbsp;4(p)</U>, <U>Section</U><U></U><U>&nbsp;4(q)</U> and <U>Section</U><U></U><U>&nbsp;4(r)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>No
Injunction</U>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory
organization having authority over the matters contemplated hereby that prohibits or directly and materially adversely affects any of the transactions contemplated by this Agreement, and no proceeding shall have been commenced that may have the
effect of prohibiting or materially adversely affecting any of the transactions contemplated by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) <U>Material Adverse
Changes</U>. Except as disclosed in the Prospectus and the Time of Sale Information, (a)&nbsp;in the judgment of the Agent there shall not have occurred any Material Adverse Change; and (b)&nbsp;there shall not have occurred any downgrading, nor
shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its
subsidiaries by any &#147;nationally recognized statistical rating organization&#148; as such term is defined for purposes of Section&nbsp;3(a)(62) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) <U>No Suspension of Trading in or Delisting of Common Shares; Other Events</U>. The trading of the Common Shares (including without
limitation the Shares) shall not have been suspended by the Commission, the Principal Market or FINRA and the Common Shares (including without limitation the Shares) shall have been approved for listing or quotation on and shall not have been
delisted from the Nasdaq Stock Market, the New York Stock Exchange or any of their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constituent markets. There shall not have occurred (and be continuing in the case of occurrences under clauses (i)&nbsp;and (ii) below) any of the following: (i)&nbsp;trading or quotation in any
of the Company&#146;s securities shall have been suspended or limited by the Commission or by the Principal Market or trading in securities generally on either the Principal Market shall have been suspended or limited, or minimum or maximum prices
shall have been generally established on any of such stock exchanges by the Commission or the FINRA; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal or New York, authorities; or (iii)&nbsp;there shall have occurred
any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change
in United States&#146; or international political, financial or economic conditions, as in the judgment of the Agent is material and adverse and makes it impracticable to market the Shares in the manner and on the terms described in the Prospectus
or to enforce contracts for the sale of securities. Additionally, the Company shall meet the then-applicable requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, which, for the avoidance of doubt, will
consist of the Registrant Requirements under General Instructions I. A of Form <FONT STYLE="white-space:nowrap">S-3</FONT> and one or more of the Transaction Requirements under General Instructions I.B of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> pursuant to which the Shares may be issued and sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Documents Required to be
Delivered on each Issuance Notice Date</U>. The Agent&#146;s obligation to use its commercially reasonable efforts to place Shares hereunder shall additionally be conditioned upon the delivery to the Agent on or before the Issuance Notice Date of a
certificate in form and substance reasonably satisfactory to the Agent, executed by the Chief Executive Officer, President or Chief Financial Officer of the Company, to the effect that all conditions to the delivery of such Issuance Notice shall
have been satisfied as at the date of such certificate (which certificate shall not be required if the foregoing representations shall be set forth in the Issuance Notice). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Misstatement or Material Omission</U>. Agent shall not have advised the Company that (i)&nbsp;the Registration Statement or any
post-effective amendment thereto contains any untrue statement of a material fact that in the Agent&#146;s reasonable opinion is material, or omits to state a fact that in the Agent&#146;s reasonable opinion is material and is required to be stated
therein or necessary to make the statements therein not misleading and (ii)&nbsp;the Prospectus or the Time of Sale Information, or any amendment or supplement thereto, includes an untrue statement of fact that in the Agent&#146;s reasonable opinion
is material, or omits to state a fact that in the Agent&#146;s reasonable opinion is material and is necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Agent Counsel Legal Opinion</U>. Agent shall have received from Cooley LLP, counsel for Agent, such opinion or opinions, on or before
the date on which the delivery of the Company counsel legal opinion is required pursuant to <U>Section</U><U></U><U>&nbsp;4(p)</U>, with respect to such matters as Agent may reasonably require, and the Company shall have furnished to such counsel
such documents as they request for enabling them to pass upon such matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. INDEMNIFICATION AND CONTRIBUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Indemnification of the Agent</U>. The Company agrees to indemnify and hold harmless the Agent, its officers and employees, and each
person, if any, who controls the Agent within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Agent or such officer, employee or controlling person may become
subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in
settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material
fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required
to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or
filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading and to reimburse the Agent and each such officer, employee and controlling person for any and all expenses (including the fees and disbursements of counsel chosen
by the Agent) as such expenses are reasonably incurred by the Agent or such officer, employee or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or
action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement
or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any
amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company consists of the information described in subsection (b)&nbsp;below. The indemnity agreement set forth in this
<U>Section</U><U></U><U>&nbsp;6(a)</U> shall be in addition to any liabilities that the Company may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Indemnification of the Company, its Directors and Officers</U>. The Agent agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls
the Company within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which the Company or any such director, officer or controlling person may become subject, under the
Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any
litigation), arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, including any information deemed to be a part thereof
pursuant to Rule 430B under the Securities Act, or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged
untrue statement of a material fact contained in any Free Writing Prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act or the Prospectus (or any amendment or supplement
thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; but, for each of (i)&nbsp;and (ii) above,
only to the extent arising out of or based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information furnished to the Company by the Agent
expressly for use in the Registration Statement, any such Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information furnished by the Agent to the Company
consists of the information set forth in the first sentence of the ninth paragraph under the caption &#147;Plan of Distribution&#148; in the Prospectus, and to reimburse the Company and each such director, officer and controlling person for any and
all reasonable and documented expenses (including the reasonable and documented fees and disbursements of one counsel chosen by the Company) as such expenses are reasonably incurred by the Company or such officer, director or controlling person in
connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The indemnity agreement set forth in this <U>Section</U><U></U><U>&nbsp;6(b)</U> shall be in addition to any
liabilities that the Agent or the Company may otherwise have. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Notifications and Other Indemnification Procedures</U>. Promptly
after receipt by an indemnified party under this <U>Section</U><U></U><U>&nbsp;6</U> of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this
<U>Section</U><U></U><U>&nbsp;6</U>, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party for
contribution or otherwise than under the indemnity agreement contained in this <U>Section</U><U></U><U>&nbsp;6</U> or to the extent it is not prejudiced as a proximate result of such failure. In case any such action is brought against any
indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying
parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party;
provided, however, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party
and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the
indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the
indemnifying party to such indemnified party of such indemnifying party&#146;s election so to assume the defense of such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party
under this <U>Section</U><U></U><U>&nbsp;6</U> for any reasonable and documented legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i)&nbsp;the indemnified party shall have employed
separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with local counsel),
representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by the indemnified party (in the case of counsel for the indemnified parties referred
to in <U>Section</U><U></U><U>&nbsp;6(a)</U> and <U>Section</U><U></U><U>&nbsp;6(b)</U> above), (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable
time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses
of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Settlements</U>. The indemnifying party under this
<U>Section</U><U></U><U>&nbsp;6</U> shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to
indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel as contemplated by <U>Section</U><U></U><U>&nbsp;6(c)</U> hereof, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its
written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request; and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with
such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action,
suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional
release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<U>Contribution</U>. If the indemnification provided for in this <U>Section</U><U></U><U>&nbsp;6</U> is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims,
damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses
referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand, from the offering of the Shares pursuant to this Agreement; or
(ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the
Company, on the one hand, and the Agent, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative
benefits received by the Company, on the one hand, and the Agent, on the other hand, in connection with the offering of the Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total gross proceeds from
the offering of the Shares (before deducting expenses) received by the Company bear to the total commissions received by the Agent. The relative fault of the Company, on the one hand, and the Agent, on the other hand, shall be determined by
reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Agent, on the
other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in <U>Section</U><U></U><U>&nbsp;6(c)</U>, any reasonable and documented legal or other fees or expenses reasonably incurred by such party in
connection with investigating or defending any action or claim. The provisions set forth in <U>Section</U><U></U><U>&nbsp;6(c)</U> with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this
<U>Section</U><U></U><U>&nbsp;6(e)</U>; provided, however, that no additional notice shall be required with respect to any action for which notice has been given under <U>Section</U><U></U><U>&nbsp;6(c)</U> for purposes of indemnification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Agent agree that it would not be just and equitable if contribution pursuant to this
<U>Section</U><U></U><U>&nbsp;6(e)</U> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this <U>Section</U><U></U><U>&nbsp;6(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, the Agent shall not be required to contribute any amount in
excess of the Selling Commission received by the Agent in connection with the offering contemplated hereby. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this <U>Section</U><U></U><U>&nbsp;6(e)</U>, each officer and employee of the Agent and each person, if any, who controls the Agent within the
meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as the Agent, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the
Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7. TERMINATION&nbsp;&amp; SURVIVAL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Term</U>. Subject to the provisions of this <U>Section</U><U></U><U>&nbsp;7</U>, the term of this Agreement shall continue from the date
of this Agreement until the end of the Agency Period, unless earlier terminated by the parties to this Agreement pursuant to this <U>Section</U><U></U><U>&nbsp;7</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Termination; Survival Following Termination</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Either party may terminate this Agreement prior to the end of the Agency Period, by giving written notice as required by this Agreement,
upon ten (10)&nbsp;Trading Days&#146; notice to the other party; provided that, (A)&nbsp;if the Company terminates this Agreement after the Agent confirms to the Company any sale of Shares, the Company shall remain obligated to comply with
<U>Section</U><U></U><U>&nbsp;3(b)(v)</U> with respect to such Shares and (B)<U>&nbsp;Section</U><U></U><U>&nbsp;2</U>, <U>Section</U><U></U><U>&nbsp;3(d)</U>, <U>Section</U><U></U><U>&nbsp;6</U>, <U>Section</U><U></U><U>&nbsp;7</U> and
<U>Section</U><U></U><U>&nbsp;8</U> shall survive termination of this Agreement. If termination shall occur prior to the Settlement Date for any sale of Shares, such sale shall nevertheless settle in accordance with the terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In addition to the survival provision of <U>Section</U><U></U><U>&nbsp;7(b)(i)</U>, the respective indemnities, agreements,
representations, warranties and other statements of the Company, of its officers and of the Agent set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Agent
or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Shares sold hereunder and any
termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8. MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Press Releases and Disclosure</U>. The Company may issue a press release describing the material terms of the transactions contemplated
hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form 8 K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated
hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably
satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (except any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any
of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of
applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all
commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Advisory or Fiduciary Relationship</U>. The Company acknowledges and agrees that (i)&nbsp;the transactions contemplated by this
Agreement, including the determination of any fees, are <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transactions between the Company and the Agent, (ii)&nbsp;when acting as a principal under this Agreement, the Agent is and
has been acting solely as a principal is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (iii)&nbsp;the Agent has not assumed nor will assume an advisory or fiduciary responsibility in favor
of the Company with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Agent has advised or is currently advising the Company on other matters) and the Agent does not have any obligation to
the Company with respect to the transactions contemplated hereby except the obligations expressly set forth in this Agreement, (iv)&nbsp;the Agent and its affiliates may be engaged in a broad range of transactions that involve interests that differ
from those of the Company, and (v)&nbsp;the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax
advisors to the extent it deemed appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Research Analyst Independence</U>. The Company acknowledges that the Agent&#146;s
research analysts and research departments are required to and should be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and as such the Agent&#146;s research analysts may
hold views and make statements or investment recommendations and/or publish research reports with respect to the Company or the offering that differ from the views of their respective investment banking divisions. The Company understands that the
Agent is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities
of the companies that may be the subject of the transactions contemplated by this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Notices</U>. All communications hereunder shall be in writing and shall be mailed,
hand delivered, sent via electronic mail (if applicable) or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">If to the Agent:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">520 Madison
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10022 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT STYLE="white-space:nowrap">786-5719</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">with
a copy (which shall not constitute notice) to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York, NY
10001 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: Daniel I. Goldberg, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (212) <FONT STYLE="white-space:nowrap">479-6275</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Lexicon
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2445 Technology Forest Blvd., 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Woodlands, Texas 77381 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Phone: (281) <FONT STYLE="white-space:nowrap">863-3000</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Vinson&nbsp;&amp; Elkins L.L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">845 Texas Ave, Suite 4700 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Houston, Texas 77002 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention:
David Oelman, Jackson O&#146;Maley </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Phone: (713) <FONT STYLE="white-space:nowrap">758-2222</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others in accordance with this
<U>Section</U><U></U><U>&nbsp;8(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Successors</U>. This Agreement will inure to the benefit of and be binding upon the
parties hereto, and to the benefit of the employees, officers and directors and controlling persons referred to in <U>Section</U><U></U><U>&nbsp;6</U>, and in each case their respective successors, and no other person will have any right or
obligation hereunder. The term &#147;successors&#148; shall not include any purchaser of the Shares as such from the Agent merely by reason of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Partial Unenforceability</U>. The invalidity or unenforceability of any Article, Section, paragraph or provision of this Agreement
shall not affect the validity or enforceability of any other Article, Section, paragraph or provision hereof. If any Article, Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall
be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Governing Law Provisions</U>. This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby may
be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York
(collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction
is <FONT STYLE="white-space:nowrap">non-exclusive)</FONT> of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&#146;s address set forth above shall be effective service of
process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and
unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>General Provisions</U>. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior
written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. Effective concurrently with the execution of this Agreement and evidenced by the Company and the Agent&#146;s
signatures hereto, the Company and the Agent hereby agree to terminate that certain Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> dated October&nbsp;30, 2020, by and between the Company and the Agent, in
accordance with <U>Section</U><U></U><U>&nbsp;7(b)</U> thereto, and each of the Company and the Agent hereby agrees that any notice required to be provided to the other by such section has been either satisfied or waived, in either case evidenced by
the Company and the Agent&#146;s signatures hereto. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and
may be delivered by facsimile transmission or by electronic delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic
Signatures and Records Act or other applicable law, e.g., www.docusign.com). This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in
writing by each party whom the condition is meant to benefit. The Article and Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Immediately Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LEXICON PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey L. Wade</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Jeffrey L. Wade</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Agreement is hereby confirmed and accepted by the Agent in New York, New York as of the
date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>JEFFERIES LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald Lynaugh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Donald Lynaugh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ISSUANCE NOTICE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: [__________] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the Open Market Sale Agreement<SUP STYLE="font-size:75%; vertical-align:top">SM</SUP> between Lexicon Pharmaceuticals, Inc. (the
&#147;<B>Company</B>&#148;) and Jefferies LLC (the &#147;<B>Agent</B>&#148;) dated as of December 29, 2023. The Company confirms that all conditions to the delivery of this Issuance Notice are satisfied as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Delivery of Issuance Notice (determined pursuant to <U>Section</U><U></U><U>&nbsp;3(b)(i)</U>): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">___________________________ </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Issuance Amount (equal to the total
Sales Price for such Shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of days in selling period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First date of selling period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Last date of selling period:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Settlement Date(s) if other than standard T+2 settlement:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Floor Price: $ ____ per share</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Comments:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</U></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Company </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Jeff Wade &#150; President and Chief Financial Officer </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Brian Crum &#150; Senior Vice President and General Counsel </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kristen Alexander &#150; Vice President, Finance and Accounting </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>The Agent </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Donald Lynaugh </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Michael Magarro </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dustin Tyner </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d673597dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g673597g1227233452928.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;29, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lexicon Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Technology Forest Place </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Woodlands, TX 77381 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel for Lexicon Pharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), with respect to certain
legal matters in connection with the proposed issuance and sale from time to time by the Company of common stock, par value $0.001 (the &#147;<U>Common Stock</U>&#148;), having an aggregate offering price of up to $75,000,000 (the
&#147;<U>Shares</U>&#148;), pursuant to that certain Open Market Sale Agreement, dated December&nbsp;29, 2023 (the &#147;<U>Sales Agreement</U>&#148;) by and between the Company and Jefferies LLC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have participated in the preparation of a Prospectus Supplement dated December&nbsp;29, 2023 (the &#147;<U>Prospectus
Supplement</U>&#148;), forming part of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) on August&nbsp;6, 2021, and declared effective by the
SEC on September&nbsp;14, 2021 (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-258564)</FONT> (the &#147;<U>Registration Statement</U>&#148;), which also contains a base prospectus (the &#147;<U>Base Prospectus</U>&#148; and, together with the
Prospectus Supplement, the &#147;<U>Prospectus</U>&#148;). The Prospectus Supplement has been filed pursuant to Rule 424(b) promulgated under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering the opinions set forth below, we have examined and relied upon (i)&nbsp;the Registration Statement and the Prospectus;
(ii)&nbsp;the Fifth Amended and Restated Certificate of Incorporation of the Company, as amended to the date hereof; (iii)&nbsp;the Second Amended and Restated Bylaws of the Company, as amended to the date hereof; (iv)&nbsp;the Sales Agreement;
(v)&nbsp;resolutions of the Board of Directors of the Company dated December&nbsp;7, 2023; and (vi)&nbsp;such other certificates and other instruments and documents as we consider appropriate for purposes of the opinions hereafter expressed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have assumed that all Shares will be issued and sold in the manner stated in the Prospectus and the Sales
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing and subject to the assumptions, exceptions, limitations and qualifications set forth herein, we are
of the opinion that the Shares, when issued and delivered against payment therefor in accordance with the Sales Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vinson&nbsp;&amp; Elkins LLP Attorneys at Law</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin Dallas Dubai Houston London Los Angeles</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">New York Richmond
San Francisco Tokyo Washington</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">845 Texas Avenue, Suite 4700</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston, TX
77002</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Tel +1.713.758.2222 Fax +1.713.758.2346 velaw.com</P></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g673597g1227233453412.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">December&nbsp;29, 2023 Page 2</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinions expressed herein are qualified in the following respects: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. We have assumed that (i)&nbsp;each document submitted to us for review is accurate and complete, each such document that is an original is
authentic, each such document that is a copy conforms to an authentic original and all signatures on each such document are genuine, and (ii)&nbsp;each certificate from governmental officials reviewed by us is accurate, complete and authentic, and
all official public records are accurate and complete. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. This opinion is limited in all respects to the federal laws of the United
States, the Delaware General Corporation Law and the Constitution of the State of Delaware, as interpreted by the courts of the State of Delaware and of the United States. We are expressing no opinion as to the effect of the laws of any other
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as Exhibit 5.1 to the Company&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> dated on or about the date hereof, to the incorporation by reference of this opinion into the Registration Statement and to the reference to our firm under the caption &#147;Legal Matters&#148; in the Prospectus
forming a part of the Registration Statement. In giving this consent, we do not hereby admit that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><I>/s/ Vinson&nbsp;&amp; Elkins L.L.P.</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Vinson&nbsp;&amp; Elkins L.L.P.</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>lxrx-20231229.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/30/2023 1:34:53 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:lxrx="http://www.lexpharma.com/20231229"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.lexpharma.com/20231229"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20231229_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20231229_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lxrx-20231229_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/30/2023 1:34:53 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lxrx-20231229_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/30/2023 1:34:53 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lxrx-20231229.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g673597g1227233452928.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g673597g1227233452928.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  6 *P# 2(  A$! Q$!_\0
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G@A$*QJ[*<C?C[V#@XX''2MN.-(HDBC4*B*%51V Z444FVQI)'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g673597g1227233453412.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g673597g1227233453412.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 #0# 2(  A$! Q$!_\0
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LT452UT(EIJBO<:=<>)IVU"_NHO-X15C@P%4#IRQ[D_G1111S-:(%!/5G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140335838964800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 29, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 29,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d673597d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lxrx-20231229.xsd" xlink:type="simple"/>
    <context id="duration_2023-12-29_to_2023-12-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-12-29_to_2023-12-29">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-12-29_to_2023-12-29"
      id="Hidden_dei_EntityCentralIndexKey">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-12-29_to_2023-12-29">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-12-29_to_2023-12-29">2023-12-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-12-29_to_2023-12-29">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-12-29_to_2023-12-29">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-12-29_to_2023-12-29">000-30111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-12-29_to_2023-12-29">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-12-29_to_2023-12-29">2445 Technology Forest Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-12-29_to_2023-12-29">11th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-12-29_to_2023-12-29">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-12-29_to_2023-12-29">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-12-29_to_2023-12-29">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-12-29_to_2023-12-29">(281)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-12-29_to_2023-12-29">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="duration_2023-12-29_to_2023-12-29">Common stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-12-29_to_2023-12-29">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-12-29_to_2023-12-29">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="duration_2023-12-29_to_2023-12-29">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-12-29_to_2023-12-29">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-12-29_to_2023-12-29">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-12-29_to_2023-12-29">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-12-29_to_2023-12-29">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/UY_ 5!+ 0(4 Q0    ( )V+G5<'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ G8N=5RIQ-.[O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ G8N=5YE<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " "=BYU7&=CR;&H$   ^$0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ G8N=5Y^@&_"Q @  X@P   T              ( !K@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " "=BYU7EXJ[',     3 @  "P
M    @ &*#P  7W)E;',O+G)E;'-02P$"% ,4    " "=BYU7'#AEZC\!   \
M @  #P              @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ G8N=5R0>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ G8N=5V60>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d673597d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d673597d8k.htm">d673597d8k.htm</File>
    <File>lxrx-20231229.xsd</File>
    <File>lxrx-20231229_lab.xml</File>
    <File>lxrx-20231229_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d673597d8k.htm": {
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20231229",
   "dts": {
    "inline": {
     "local": [
      "d673597d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20231229.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20231229_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20231229_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-12-29_to_2023-12-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d673597d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-12-29_to_2023-12-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d673597d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.lexpharma.com//20231229/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-306032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-306032-xbrl.zip
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MI),:W$T:2JW:S<;1"OIMB_2!R;*V#6CKPVS%YU_N/LR:1\7M9TUK4<A]W5?
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M4MLJQ#^%*"'5!(,$BF;1(I7CMUWM7(;*; 2<-IH]LNRM41E6%A0B0N5\*;.
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MAE.QW 0MP4IXGVKB8*A@YF76#]6(12!_? 3_EN&14,6#+-%9A@1QSP, 0_V
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MX%4^V'((5Q :H"58,B@<MSN]<;P9O%SGWL%AX.$":;L>04"GH(XH '>M@-H
MC32-L2]"/90![3NA0SXR!SI L/ ]&T@"J\:A$8")K:'HT[0X!+Q68_& 3(^&
MG'K"'N!9R%+P10R)U!:$31 "$:&8("B#B5/_)#*([!X>HT!18%W*RY&'TJ5P
M.,:G3$@I)W-(@74YSYZL((Q\"L"F(1\@ U;#P%D(3%EQ8M#W6"&D<2@"%8O#
M!C<D6L41%=*0@3DR1@ [8^2$B0YY-]UJ)%T'@!<$/8T\!*<_5+'G+F6E,U1*
M$Y8L8&;.;J !!AAMI$7*:E1,*\^=V<?B$#/^ >,%IEI$D7) @XEM&6U&1/J
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M>6P[T:6<(#D>\E69VA9HC-ER@OO@3UKP0;#'KF+Y=/@'&I[\!3>>_]HUSN$
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M@UZA/5:#;-YY7VW*O.+]! 4R6+B9LPGZ;_0BC-J@SEA@&H75?)X09S07L='
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M>N%"U7 =@]JD>+^[5B4*2U7NFP#4FTI80W!SI6Q8:KTDS>F;[H59!5>U90R
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MY-14Q(?5LLY*U1AJJV:34O352K*.L&G !HN']C*XW3DL_LM69**#+VDX4*"
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M!N*B3!'\K-8AJZYY46O'#.+DJ6\+ZF .*SFY=?"Q25(G(^3A[^_(#6_GIP2
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MM'_JU=UGMB 4'4D66J(,>4;8^62=3+M=_LCAW:P!10: :'YG9XW[WP$7_G"
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M@]'5Y&Z4&AK:'%N@-%ND-;)<97MNML-\:"$0LYO'98"<4-AT%8T'-4I:IN*
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M*==9#/NSL#$O2+MP3&J,7G'AEI+/Z<"X&*IQB$++UM=O4E,.\ ,29"@$?";
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M7O7@5R$-K4&[[)?9;DB@-"Q=EUKEP4[Y_E<U^Z9*FYB)F]UPW&/;Y[Y6F?[
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M"?K',#3DGTJV!+PN UR +H0+.[:!.M3M7"!BGOX^?"-N!7^@+&AX6Z=*XR4
M7V7,1/V36#3TC;HM\9_=V%#H%-5PAZ 5*W63T, /XCC<<IGXT=]TU?P>IUGA
M)8R"V91I$/8BT<; H-K2$&250)7"O&_9GHVZ ;#VXO@.H#8HB-\$^/V<KMX
M-#7.#X\YO?]WH(,$;OIS7BOC<(K?Y]Z[?Y;-NH&H7\J-;I><-;Q??IC7$9"5
M!KCYN N89BTD.%-Q2-6Q[ANVTV\9TB9-NX%Z1X*U4",Q',UG-(FL5\W#O(Y
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M-C<S-3DW9&5X,3$N:'1M4$L! A0#%     @ G8N=5_<5J45+"@  G2,  !
M             ( !=[$  &0V-S,U.3=D97@U,2YH=&U02P$"% ,4    " "=
MBYU7AJ8U@#H#  !0"P  $0              @ 'PNP  ;'AR>"TR,#(S,3(R
M.2YX<V102P$"% ,4    " "=BYU7O?G_#W@&  "Z1@  %0
M@ %9OP  ;'AR>"TR,#(S,3(R.5]L86(N>&UL4$L! A0#%     @ G8N=5W,E
ME]F_!   0BP  !4              ( !!,8  &QX<G@M,C R,S$R,CE?<')E
:+GAM;%!+!08     !@ & 'T!  #VR@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
